1.
Int J Dermatol
; 63(4): 526-527, 2024 Apr.
Article
in English
| MEDLINE
| ID: mdl-38149498
2.
CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Ital J Dermatol Venerol
; 158(4): 292-301, 2023 Aug.
Article
in English
| MEDLINE
| ID: mdl-37539500
ABSTRACT
Melanoma risk stratification is crucial for both patients and physicians. Patients want to understand what to expect after diagnosis, and physicians need to decide on an appropriate treatment plan. Traditionally, risk stratification has been based on Breslow thickness and sentinel lymph node (SLN) status. However, the introduction of CP-GEP (Merlin) has provided a molecular test that can be performed on primary melanoma diagnostic biopsy tissue, offering additional risk stratification beyond established variables. In this review, we assess the utility of CP-GEP testing compared to clinicopathologic variables and SLN status and propose a multilayered approach to selecting patients for adjuvant therapy using CP-GEP technology.
Subject(s)
Melanoma , Skin Neoplasms , Humans , Sentinel Lymph Node Biopsy , Skin Neoplasms/genetics , Neurofibromin 2/genetics , Lymphatic Metastasis/genetics , Melanoma/genetics , Gene Expression Profiling
3.
Int J Dermatol
; 62(6): e329-e330, 2023 06.
Article
in English
| MEDLINE
| ID: mdl-35959518